Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Friendship Hospital
About this trial
This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.
Eligibility criteria
Qualifiers
Met HLH-2004 diagnostic criteria;
Active infection；
Empirical treatment with carbapenems did not respond after 72 hours；
Age >18 years old, no gender limitation;
Disqualifiers
Other antibiotics should be selected according to the results of drug sensitivity；
Systemic antibiotics other than carbapenems are used with 72 hours；
Inability to take oral medications due to disease of gastrointestinal tract；
Severe liver insufficiency;
Trial design
Treatments tested in this trial
- Carrimycin tablets
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
1Beijing Friendship Hospital, Capital Medical University100050, BeijingBeijing Municipality, China
Sponsors and collaborators
Beijing Friendship Hospital
Lead sponsor
Source ClinicalTrials.gov